Cargando…

Tissue-Resident Lymphocytes: Implications in Immunotherapy for Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is a hard-to-treat cancer. The recent introduction of immune checkpoint inhibitors (ICIs) provided viable options to treat HCC, but the response rate is currently not sufficient. Thus, a better understanding of ICI-responding cells within tumors is needed to improve ou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Ji Won, Yoon, Seung Kew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7796120/ https://www.ncbi.nlm.nih.gov/pubmed/33379384 http://dx.doi.org/10.3390/ijms22010232

Ejemplares similares

Immune Responses Following Locoregional Treatment for Hepatocellular Carcinoma: Possible Roles of Adjuvant Immunotherapy
por: Han, Ji-Won, et al.
Publicado: (2021)

The Biology of Cancer Stem Cells and Its Clinical Implication in Hepatocellular Carcinoma
por: Yoon, Seung Kew
Publicado: (2012)

Whole blood viscosity is associated with extrahepatic metastases and survival in patients with hepatocellular carcinoma
por: Han, Ji Won, et al.
Publicado: (2021)

Immunological Markers, Prognostic Factors and Challenges Following Curative Treatments for Hepatocellular Carcinoma
por: Lee, Soon Kyu, et al.
Publicado: (2021)

Hepatocellular carcinoma: Mechanisms of progression and immunotherapy
por: Jiang, Yu, et al.
Publicado: (2019)

Hepatocellular carcinoma: epidemiology and risk factors
por: Kew, Michael C
Publicado: (2014)

Role of Exosomes in Immunotherapy of Hepatocellular Carcinoma
por: Tian, Bao-Wen, et al.
Publicado: (2022)

The emergence of tumor-infiltrating lymphocytes in nasopharyngeal carcinoma: Predictive value and immunotherapy implications
por: Yang, Liu, et al.
Publicado: (2021)

Multidisciplinary approach for hepatocellular carcinoma arising from cirrhotic liver with Budd-Chiari syndrome: a case report
por: Kim, Sangmi, et al.
Publicado: (2022)

Factors associated with the survival outcomes of patients with untreated hepatocellular carcinoma: An analysis of nationwide data
por: Kwon, Min Jung, et al.
Publicado: (2023)

Neoadjuvant Immunotherapy for Hepatocellular Carcinoma
por: Marron, Thomas U, et al.
Publicado: (2022)

Advances in Immunotherapy for Hepatocellular Carcinoma
por: Hagiwara, Satoru, et al.
Publicado: (2023)

Distinct Patterns of HBV Integration and TERT Alterations between in Tumor and Non-Tumor Tissue in Patients with Hepatocellular Carcinoma
por: Jang, Jeong-Won, et al.
Publicado: (2021)

Tissue-resident memory T cells in tumor immunity and immunotherapy
por: Okła, Karolina, et al.
Publicado: (2021)

The promise of adoptive cellular immunotherapies in hepatocellular carcinoma
por: Hendrickson, Peter G., et al.
Publicado: (2019)

Intrahepatic inflammatory IgA(+)PD-L1(high) monocytes in hepatocellular carcinoma development and immunotherapy
por: Sung, Pil Soo, et al.
Publicado: (2022)

Advances in immunotherapy for hepatocellular carcinoma
por: Sangro, Bruno, et al.
Publicado: (2021)

Rapidly Progressing Budd-Chiari Syndrome Complicated by Hepatocellular Carcinoma
por: Jang, Jeong Won, et al.
Publicado: (2003)

Tissue-resident lymphocytes: weaponized sentinels at barrier surfaces
por: Belz, Gabrielle T., et al.
Publicado: (2020)

Recent Advances in Immunotherapy for Hepatocellular Carcinoma
por: Nakano, Shigeharu, et al.
Publicado: (2020)

Immunotherapy for hepatocellular carcinoma: Current and future
por: Johnston, Michael P, et al.
Publicado: (2019)

Mouse Models for Immunotherapy in Hepatocellular Carcinoma
por: Li, Enya, et al.
Publicado: (2019)

Immunotherapy Updates in Advanced Hepatocellular Carcinoma
por: Singh, Amisha, et al.
Publicado: (2021)

NASH and Hepatocellular Carcinoma: Immunology and Immunotherapy
por: Pinter, Matthias, et al.
Publicado: (2023)

Immunotherapy for advanced or recurrent hepatocellular carcinoma
por: Luo, Ying-Zhe, et al.
Publicado: (2023)

Mechanisms of Resistance to Immunotherapy in Hepatocellular Carcinoma
por: Manfredi, Giulia Francesca, et al.
Publicado: (2023)

Advances in Immunotherapy for Hepatocellular Carcinoma (HCC)
por: Bicer, Fuat, et al.
Publicado: (2023)

An Immunological Perspective on the Mechanism of Drug Induced Liver Injury: Focused on Drugs for Treatment of Hepatocellular Carcinoma and Liver Transplantation
por: Lee, Soon Kyu, et al.
Publicado: (2023)

Application of Helical Tomotherapy for Two Cases of Advanced Hepatocellular Carcinoma
por: Kim, Joon Sung, et al.
Publicado: (2011)

Diagnostic performance of serum exosomal miRNA-720 in hepatocellular carcinoma
por: Jang, Jeong Won, et al.
Publicado: (2022)

Serum and tissue markers in hepatocellular carcinoma and cholangiocarcinoma: clinical and prognostic implications
por: Berretta, Massimiliano, et al.
Publicado: (2016)

Tissue-resident lymphocytes: sentinel of the transformed tissue
por: Dadi, Saïda, et al.
Publicado: (2017)

Hepatocellular Carcinoma—The Influence of Immunoanatomy and the Role of Immunotherapy
por: Patel, Keyur, et al.
Publicado: (2020)

Immunotherapy for Hepatocellular Carcinoma: A 2021 Update
por: Kole, Christo, et al.
Publicado: (2020)

Real-World Use of Immunotherapy for Hepatocellular Carcinoma
por: Sara, Amir, et al.
Publicado: (2023)

Computational Characterizing Necroptosis Reveals Implications for Immune Infiltration and Immunotherapy of Hepatocellular Carcinoma
por: Zhu, Jun, et al.
Publicado: (2022)

The Potential of Tissue-Resident Memory T Cells for Adoptive Immunotherapy against Cancer
por: Beumer-Chuwonpad, Ammarina, et al.
Publicado: (2021)

Immunotherapy in Hepatocellular Carcinoma
por: Fulgenzi, Claudia A. M., et al.
Publicado: (2021)

Immunotherapies for hepatocellular carcinoma
por: Liu, Justin K. H., et al.
Publicado: (2021)

Significance of an increase in the Child-Pugh score after radiotherapy in patients with unresectable hepatocellular carcinoma
por: Son, Seok Hyun, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_onstvav7kb4i9b2vo50hvcrnuq